ClinicaliQ Trial Snapshot
- Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study — Recruiting • Oncology • NCT06987045.
- Testing focus: This study establishes PSA reference intervals (normal ranges) specifically for trans women and non-binary individuals with prostates, addressing a current evidence gap as existing PSA reference ranges are derived solely from cisgender men.
- Patient eligibility: The study includes trans women and non-binary people aged 18+ who have a prostate, regardless of hormone therapy status or surgical history, ensuring diverse representation across the trans and non-binary population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people. Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group TransPRIDE is a research study that will help us…
Eligibility Snapshot
- : * • Aged >40 * Transgender or non-binary (identify with a gender other than the one assigned at birth) * With a prostate * Fulfills at least one of the following 3 criteria with regards to gender-affirming medical care: * Taking oestradiol for at least the last 3 months * Taking anti-androgens for at least the last 3 months * Ever had bilateral orchidectomy * Eligible for National Health Service (NHS) treatment
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.